The Institute of Medicine organized a meeting for behavior experts, statisticians and scientists to help guide the Food and Drug Administration (FDA), which has faced criticism for its handling of issues such as suicide risk among youths who take antidepressants and heart risks of the now-withdrawn arthritis drug Vioxx.
At a workshop that discussed risks and benefits of prescription drugs, panelists called for:
Less advertising hype and more information to help patients and doctors decide whether to take prescription drugs
Simpler information on drug risks and benefits, such as graphics and charts of basic facts and drug comparisons
Toning down drug advertisements so patients can make logical choices
FDA officials said the agency would consider the advice, but noted that the current issues are not as serious as past issues that have called for major changes at the FDA.
While in 2005 the drug industry voluntarily made their ads more balanced, they also spent $11 billion on drug ads for consumers and promotions for doctors.